vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-963Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSОПЫТ ПРИМЕНЕНИЯ ИНФЛИКСИМАБА У БОЛЬНОЙ С РАННИМ ПОЛИАРТИКУЛЯРНЫМ ЮВЕНИЛЬНЫМ РЕВМАТОИДНЫМ АРТРИТОМTREATMENT WITH INFLIXIMAB IN PATIENT WITH EARLY POLYARTICULAR JUVENILE RHEUMATOID ARTHRITISСлепцоваТ.В.SleptsovaT.V.АлексееваЕ.И.AlexeevaE.I.ВалиеваС.И.ValievaS.I.БзароваТ.М.BzarovaT.M.ЛисицинА.О.LisitsinA.O.ИсаеваК.Б.IsaevaK.B.ДенисоваР.В.DenisovaR.V.Научный центр здоровья детей РАМН, МоскваРоссияScientific Center of Children’s Health, Russian Academy of Medical Sciences, MoscowRussian FederationНаучный центр здоровья детей РАМН, Москва
Первый московский государственный медицинский университет им. И.М. СеченоваРоссияScientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow
I.M. Sechenov 1st Moscow State Medical UniversityRussian Federation20101709201595Вопросы современной педиатрии127132Copyright © Слепцова Т., Алексеева Е., Валиева С., Бзарова Т., Лисицин А., Исаева К., Денисова Р., 20102010Слепцова Т., Алексеева Е., Валиева С., Бзарова Т., Лисицин А., Исаева К., Денисова Р.Sleptsova T., Alexeeva E., Valieva S., Bzarova T., Lisitsin A., Isaeva K., Denisova R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/963ReferencesBradley J.R. TNF–mediated inflammatory disease. J. Pathol. 2008; 214: 149–160.Bradley J.R. TNF–mediated inflammatory disease. J. Pathol. 2008; 214: 149–160.Ackermann C., Kavanaugh A. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin. Ther. Targets. 2007; 11: 1369–1384.Ackermann C., Kavanaugh A. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin. Ther. Targets. 2007; 11: 1369–1384.Smolen J.S., Han C., van der Heijde D.M. et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann. Rheum. Dis. 2009; 68(6): 823–827.Smolen J.S., Han C., van der Heijde D.M. et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann. Rheum. Dis. 2009; 68(6): 823–827.Takeuchi T., Yamanaka H., Inoue E. et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM–2J). Mod. Rheumatol. 2008; 18 (5): 447–454.Takeuchi T., Yamanaka H., Inoue E. et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM–2J). Mod. Rheumatol. 2008; 18 (5): 447–454.Pavelka K., Gatterová J., Tegzová D. et al. Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infliximab treatment. Clin. Exp. Rheumatol. 2007; 25(4): 540–555.Pavelka K., Gatterová J., Tegzová D. et al. Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infliximab treatment. Clin. Exp. Rheumatol. 2007; 25(4): 540–555.Corona F., Scarazatti M., Dell’erra L., Beltramelli M., Carnelli V., Bardare M. Active refractory juvenile idiopathic arthritis: treatment with infliximab. Efficacy and safety. Ital. J. Pediatr. 2004; 30: 165–168.Corona F., Scarazatti M., Dell’erra L., Beltramelli M., Carnelli V., Bardare M. Active refractory juvenile idiopathic arthritis: treatment with infliximab. Efficacy and safety. Ital. J. Pediatr. 2004; 30: 165–168.Masatlioglu S., Gogus F., Cevirgen D., et al. Infliximab in the treatment of refractory juvenile idiopathic arthritis. Arthritis Rheum. 2002; 46: 481.Masatlioglu S., Gogus F., Cevirgen D., et al. Infliximab in the treatment of refractory juvenile idiopathic arthritis. Arthritis Rheum. 2002; 46: 481.Алексеева А.М. Эффективность и безопасность блокатора ФНО – инфликсимаба у больных ювенильным ревматоидным артритом. Автореферат дис. …канд. мед. наук. М. 2008. 24 с.Алексеева А.М. Эффективность и безопасность блокатора ФНО – инфликсимаба у больных ювенильным ревматоидным артритом. Автореферат дис. …канд. мед. наук. М. 2008. 24 с.Алексеева Е.И., Бзарова Т.М., Валиева С.И. и др. Эффективность лечения инфликсимабом суставных вариантов ювенильного ревматоидного артрита. XIII Российский национальный конгресс «Человек и лекарство». Тезисы докладов. М. 2006. С. 351–352.Алексеева Е.И., Бзарова Т.М., Валиева С.И. и др. Эффективность лечения инфликсимабом суставных вариантов ювенильного ревматоидного артрита. XIII Российский национальный конгресс «Человек и лекарство». Тезисы докладов. М. 2006. С. 351–352.Chaturvedi V.P. Pilot study of chimeric monoclonal anti-tumor necrosis factor alpha anti-body (infliximab) with methotrexate in polyarticular juvenile idiopathic arthritis [abstract]. American College of Rheumatology 66th Annual Scientific Meeting. October 24–25, 2002. New Orleans. LA. Abstract LB12.Chaturvedi V.P. Pilot study of chimeric monoclonal anti-tumor necrosis factor alpha anti-body (infliximab) with methotrexate in polyarticular juvenile idiopathic arthritis [abstract]. American College of Rheumatology 66th Annual Scientific Meeting. October 24–25, 2002. New Orleans. LA. Abstract LB12.Lovell D.J., Ruperto N., Cuttica R. et al. Randomized trial of infliximab plus methotrexate for the treatment of polyarticular juvenile rheumatoid arthritis [poster]. American College of Rheumatology 68th Annual Scientific Meeting, October 16–21, 2004. San Antonio. TX. Poster 523.Lovell D.J., Ruperto N., Cuttica R. et al. Randomized trial of infliximab plus methotrexate for the treatment of polyarticular juvenile rheumatoid arthritis [poster]. American College of Rheumatology 68th Annual Scientific Meeting, October 16–21, 2004. San Antonio. TX. Poster 523.Mangge H., Heinzl B., Grubbauer H-M. et al. Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis. Rheumatol. Int. 2003; 23: 258–261.Mangge H., Heinzl B., Grubbauer H-M. et al. Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis. Rheumatol. Int. 2003; 23: 258–261.Allaart C.F., Breedveld F.C., Dijkmans BA. et al. Treatment of recent onset rheumatoid arthritis: lessons from the BeSt study. J. Rheumatol. Suppl. 2007; 80(10): 25–33.Allaart C.F., Breedveld F.C., Dijkmans BA. et al. Treatment of recent onset rheumatoid arthritis: lessons from the BeSt study. J. Rheumatol. Suppl. 2007; 80(10): 25–33.Van der Kooij S.M., le Cessie S., Goekoop–Ruiterman Y.P. et.al. Clinical and radiological efficacy of initial delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann. Rheum. Dis. 2009; 68 (7): 1153–1158.Van der Kooij S.M., le Cessie S., Goekoop–Ruiterman Y.P. et.al. Clinical and radiological efficacy of initial delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann. Rheum. Dis. 2009; 68 (7): 1153–1158.Durez P., Malghem J., Nzeusseu Toukap A. et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum. 2007; 56(12): 3919–3927.Durez P., Malghem J., Nzeusseu Toukap A. et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum. 2007; 56(12): 3919–3927.Quinn M.A., Conaghan P.G., O’Connor P.J. et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve month randomized, double blind, placebo controlled trial. Arthritis Rheum. 2005; 52(1): 27–35.Quinn M.A., Conaghan P.G., O’Connor P.J. et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve month randomized, double blind, placebo controlled trial. Arthritis Rheum. 2005; 52(1): 27–35.Takeuchi T. Clinical and radiological efficacy of initial VS delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Nippon Rinsho. 2009; 67(5): 33–36.Takeuchi T. Clinical and radiological efficacy of initial VS delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Nippon Rinsho. 2009; 67(5): 33–36.Takeuchi T. Indications for and use of biologics in early rheumatoid arthritis based on the evidence. Nippon Rinsho. 2009; 67 (5): 1043–1049.Takeuchi T. Indications for and use of biologics in early rheumatoid arthritis based on the evidence. Nippon Rinsho. 2009; 67 (5): 1043–1049.
The authors declare that there are no conflicts of interest present.